Cell & Gene Therapy COGS: Progress & Pitfalls In Our Quest For Affordability
Source: Cell & Gene Collaborative
By Anna Rose Welch, Director, Cell & Gene Collaborative
In December 2021, an hour-long conversation with Dark Horse Consulting’s COO Katy Spink fortuitously led to the creation of five new year’s resolutions for the ATMP manufacturing space.
Of course, I wouldn’t go so far as to say these resolutions became less important or irrelevant at the stroke of midnight on January 1, 2023. If anything, each one of these resolutions is likely to be on our list of to-dos for as long as we have active cell and gene therapy pipelines.
A lot can be accomplished and learned in a year — and 2022 was no exception. But when it comes to understanding our products and establishing the internal/external capabilities to support them, we are an industry dedicated to “relentless incrementalism.” Hence why I jumped at the chance to invite Spink to rejoin me and a handful of Cell & Gene Collaborative members to discuss where incremental progress had been made in chipping away at some of these resolutions.
Continue reading here:
